# RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

> **NCT04525014** · PHASE1 · TERMINATED · sponsor: **EpicentRx, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Brain Tumor, Recurrent
- Brain Tumor, Pediatric
- Central Nervous System Neoplasms
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** RRx-001
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT04525014
- **Lead sponsor:** EpicentRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-26
- **Primary completion:** 2024-07-29
- **Final completion:** 2024-07-29
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low Enrollment
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04525014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04525014, "RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04525014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*